23rd Oct 2014 09:08
LONDON (Alliance News) - Cambridge Cognition Holdings PLC Thursday said it has now launched its new product, CTIS-Profile 2+.
"The new product enables Cambridge Cognition to provide pharmaceutical and biotechnology companies with cognitive safety and tolerability testing across all phases of the clinical development of new therapeutic compounds," the company said in a statement.
CTIS, stands for Clinical Trials Information System. Cambridge Cognition specialises in computerised neuropsychological tests including those enabling the early detection of dementia.
CTIS-Profile 2+ is the latest product in the company's safety and tolerability testing portfolio on the cloud computing platform, Cantab Connect, which launched in June this year.
"Following on from the launch of CTIS-Profile there has been an increasing demand from our customers to provide sensitive, intuitive and rapid cognitive testing on the Cantab Connect platform. As well as significantly reducing data errors and the labor-intensity of trials, touchscreen assessment and electronic data capture increases confidence and accelerates decision making in the clinical trial process, delivering huge benefits to clients," said Chief Scientific Officer Andrew Blackwell.
The company's stock was up 2.4% at 84.49 pence Thursday morning.
By Rowena Harris-Doughty; [email protected]; @rharrisdoughty
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Cambridge Cog